Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date	Title and Summary	View
May 15, 2020	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH PLAINFIELD, N.J. , May 15, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on May 11, 2020 it approved non-statutory stock options to purchase an aggregate of 50,025 shares of its common stock and 4,470 restricted stock units ("RSUs"), each representing the	Additional Formats
May 06, 2020	PTC Therapeutics to Acquire Censa Pharmaceuticals - Acquisition diversifies and strengthens PTC Therapeutics' rare disorders portfolio - - Compelling Phase 3 ready asset to potentially address unmet need in PKU - SOUTH PLAINFIELD, N.J. , May 6, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has entered into an	Additional Formats
May 05, 2020	PTC Therapeutics to Participate at Upcoming Investor Conferences SOUTH PLAINFIELD, N.J. , May 5, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present in a virtual format at the following conferences: 2020 BofA Securities Health Care Conference Tuesday, May 12 th at 3:40 p.m.	Additional Formats
Apr 30, 2020	PTC Therapeutics Reports First Quarter 2020 Financial Results and Provides a Corporate Update - Risdiplam demonstrated clinically meaningful and statistically significant results across broadest population of spinal muscular atrophy (SMA) patients studied to date; PDUFA date August 24, 2020 - - PTC provides an update on clinical and regulatory programs - - First quarter 2020 total revenues	Additional Formats
Apr 28, 2020	Confirmatory Part 2 of FIREFISH Demonstrates Survival and Motor Milestones Not Seen in Natural History in Infants with Type 1 Spinal Muscular Atrophy - Part 2 of pivotal study met its primary endpoint by demonstrating unsupported sitting in infants aged 1-7 months with type 1 SMA after 12 months of treatment - - Meaningful benefit observed in dose-finding Part 1 confirmed - - PDUFA expected August 24, 2020 - SOUTH PLAINFIELD, N.J.	Additional Formats
Apr 22, 2020	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH PLAINFIELD, N.J. , April 22, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 17, 2020 it approved non-statutory stock options to purchase an aggregate of 151,850 shares of its common stock and 6,260 restricted stock units ("RSUs"), each representing	Additional Formats
Apr 17, 2020	PTC Therapeutics Announces New Leadership Appointments SOUTH PLAINFIELD, N.J. , April 17, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointments of Matthew Klein , M.D., to Chief Development Officer and Eric Pauwels to Chief Business Officer. Dr. Klein will be responsible for the development of our clinical stage	Additional Formats
Apr 16, 2020	PTC Therapeutics to Host Conference Call to Discuss First Quarter 2020 Financial Results SOUTH PLAINFIELD, N.J. , April 16, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2020 financial results and provide an update on the company's business and outlook on Thursday, April 30,	Additional Formats
Apr 07, 2020	PTC Announces Regulatory Update on Risdiplam for Spinal Muscular Atrophy (SMA) - U.S. Food and Drug Administration (FDA) extends review of risdiplam by three months following submission of additional data - - Risdiplam has been studied across a broad real-world population of infants, children, teenagers and adults with Type 1, 2 or 3 SMA - - European Medicine Agency (EMA)	Additional Formats
Mar 16, 2020	PTC Therapeutics Announces Management Change SOUTH PLAINFIELD, N.J. , March 16, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Marcio Souza , Chief Operating Officer, has resigned and will be leaving the company by April 25 th , 2020. "We are grateful to Marcio for the significant contributions he has made to	Additional Formats